Drug General Information
Drug ID	D0O2XJ
Former ID	DIB013496
Drug Name	NXN-188
Synonyms	Acute migraine therapy, NeurAxon; NXN-188 (oral); NXN-188 (oral), NeurAxon
Drug Type	Small molecular drug
Indication	Migraine [ICD9: 346; ICD10:G43]		Phase 2	[522692]
Company	Neuraxon
Structure		Download 2D MOL 3D MOL
Formula	C27H36N8O5
PubChem Compound ID	123853
Target and Pathway
Target(s)	5-hydroxytryptamine 1B receptor	Target Info	Modulator
	5-hydroxytryptamine 1D receptor	Target Info	Modulator
KEGG Pathway	cAMP signaling pathway
	Neuroactive ligand-receptor interaction
	Serotonergic synapsehsa04024:cAMP signaling pathway
	Serotonergic synapse
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
	5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
	5HT1 type receptor mediated signaling pathway
Reactome	Serotonin receptors
	G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
	G alpha (i) signalling events
WikiPathways	Serotonin HTR1 Group and FOS Pathway
	Monoamine GPCRs
	GPCRs, Class A Rhodopsin-like
	GPCR ligand binding
	GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway
	GPCR downstream signaling
References
Ref 522692	ClinicalTrials.gov (NCT00920686) Study of NXN 188 for the Treatment of Migraine With Aura. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.